Patents Assigned to Imagine Institut des Maladies Genetiques Necker Enfants Malades
-
Publication number: 20230000838Abstract: A 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of sickle cell disease in a patient in need thereof. Also, a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the prevention and/or treatment of acute chest syndrome (ACS) in a sickle cell disease patient in need thereof.Type: ApplicationFiled: November 20, 2020Publication date: January 5, 2023Applicants: AB SCIENCE, UNIVERSITÉ PARIS CITÉ, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADESInventors: Alain MOUSSY, Jean-Pierre KINET, Olivier HERMINE, Thiago TROVATI MACIEL, Slimane ALLALI, Rachel RIGNAULT-BRICARD, Caroline CARVALHO
-
Patent number: 10731197Abstract: The present invention relates to a method for detecting or quantifying CTP in a cell sample comprising at least two nucleotide triphosphates by cationic ion pairing chromatography coupled to mass spectrometry, to a method for detecting or quantifying CTP synthase activity based on the method for detecting or quantifying CTP, and to their use in methods for screening potential immunosuppressive or anti-cancer compounds and in methods for determining the appropriate dose of an immunosuppressive or anti-cancer compound inhibiting CTP synthase activity for a treated subject.Type: GrantFiled: October 10, 2016Date of Patent: August 4, 2020Assignees: Assitance Publique-Hopitaux de Paris, Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Sylvia Sanquer, Anne-Claire Boschat, Sylvain Latour, Emmanuel Martin, Robert Barouki
-
Patent number: 10617658Abstract: The present invention relates to the use of hydroxycarbamide (HC) for reducing and/or delaying the extension of capillary nonperfusion, a cause of irreparable visual impairment in patients suffering from central retinal vein occlusion (CRVO). This is the first systemic treatment which makes it possible to reduce retinal ischemic complications in patients in whom (CRVO) has been recently diagnosed and is consequently in a rapidly progressive phase. Given the low toxicity of HC evaluated on a large scale in children and adults in the context of other diseases for decades, the results of the present study open up a new therapeutic approach in the treatment of CRVO.Type: GrantFiled: August 8, 2016Date of Patent: April 14, 2020Assignees: CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE QUINZE-VINGTS, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICAL (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS DESCARTESInventors: Yves Colin, Jean-Francois Girmens, Olivier Hermine, Emmanuel Heron, Michel Paques
-
Patent number: 10151745Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.Type: GrantFiled: November 21, 2013Date of Patent: December 11, 2018Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Assistance Publique—Hopitaux de Paris, Universite Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants MaladesInventors: Olivier Hermine, Marie Thérèse Rubio, Marie Bouillie, Maria Leite de Maraes
-
Publication number: 20180298420Abstract: The present invention relates to a method for detecting or quantifying CTP in a cell sample comprising at least two nucleotide triphosphates by cationic ion pairing chromatography coupled to mass spectrometry, to a method for detecting or quantifying CTP synthase activity based on the method for detecting or quantifying CTP, and to their use in methods for screening potential immunosuppressive or anti-cancer compounds and in methods for determining the appropriate dose of an immunosuppressive or anti-cancer compound inhibiting CTP synthase activity for a treated subject.Type: ApplicationFiled: October 10, 2016Publication date: October 18, 2018Applicants: Assistance Publique-Hopitaux de Paris, Imagine Institut Des Maladies Genetiques Necker Enfants Malades, Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Sylvia Sanquer, Anne-Claire Boschat, Sylvain Latour, Emmanuel Martin, Robert Barouki
-
Publication number: 20150301022Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.Type: ApplicationFiled: November 21, 2013Publication date: October 22, 2015Applicants: Assistance Publique - Hopitaux de Paris, Université Paris Descartes, Imagine Institut des Maladies Genetiques Necker Enfants MaladesInventors: Olivier Hermine, Marie Thèrèse Rubio, Marie Bouillie, Maria Leite de Maraes